Clinical Trials Sponsored by Daiichi Pharmaceuticals

Total 20268 results

Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

WHO Grade II Glioma

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Japan
Daiichi Sankyo Co., Ltd.

Terminated

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Diabetic Peripheral Neuropathic Pain

China
Daiichi Sankyo Co., Ltd.

Completed

Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Taiwan
Daiichi Sankyo, Inc.
Daiichi Sankyo UK Ltd.

Terminated

A Study of DS-2248 in Participants With Advanced Solid Tumors

Non-small Cell Lung Carcinoma | Solid Tumors

United States
Daiichi Sankyo Co., Ltd.

Completed

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

Healthy Subjects | Pharmacokinetics | Drug-drug Interaction | Quizartinib

United States
Daiichi Sankyo Co., Ltd.

Completed

Study of Mirogabalin for Central Neuropathic Pain

Central Neuropathic Pain

Japan, Korea, Republic of, Taiwan
Daiichi Sankyo Co., Ltd.

Completed

Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy

Acute Ischemic Stroke

Japan
Daiichi Sankyo Co., Ltd.

Completed

An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

Japan
Daiichi Sankyo Co., Ltd.

Completed

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

Cervical Cancer | Small Cell Lung Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | Gastric Cancer (Inoperable and Recurrent)

Japan
Daiichi Sankyo Co., Ltd.

Completed

Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs

Venous Thromboembolism

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

Venous Thromboembolism

Japan, Taiwan
Daiichi Sankyo Co., Ltd.

Completed

Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation

Atrial Fibrillation

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

Embolism and Thrombosis | Thrombosis | Deep Vein Thrombosis | Thromboembolism | Venous Thromboembolism | Arthroplasty, Replacement, Hip

Japan, Taiwan
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of Quizartinib

Relapsed AML | Refractory AML

Japan
Daiichi Sankyo Co., Ltd.

Completed

Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 in Patients With Essential Hypertension (ESAX-HTN)

Essential Hypertension

Japan
Daiichi Sankyo Co., Ltd.

Completed

Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis (DIRECT)

Osteoporosis

Japan
Daiichi Sankyo Co., Ltd.

Completed

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria

Japan, China
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
AstraZeneca

Completed

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Neoplasm, Breast | Adenocarcinoma, Gastric

Taiwan
Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast Cancer

United States, Japan
Daiichi Sankyo, Inc.
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Breast Cancer

United States, Spain, Italy, Korea, Republic of, Belgium, France, Japan, United Kingdom, Canada
AstraZeneca
Daiichi Sankyo

Recruiting

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Breast Cancer

United States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
Daiichi Sankyo, Inc.

Recruiting

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Renal Cell Carcinoma | Ovarian Tumor

Japan, United States
AstraZeneca
Daiichi Sankyo

Active, not recruiting

A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC (DL-05)

HER2-mutant Non-Small Cell Lung Cancer

China
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

Non-Small Cell Lung Cancer

United States, Spain, Korea, Republic of, Italy, France, Japan, Taiwan, Netherlands, Australia, Canada
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (DESTINY-CRC02)

Advanced Colorectal Cancer

Korea, Republic of, United States, Taiwan, Belgium, Spain, Japan, United Kingdom, France, Italy, Australia
Daiichi Sankyo, Inc.

Completed

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)

Acute Myeloid Leukemia | Leukemia

Hong Kong, Canada, Belgium, France, Spain, Taiwan, United States, Australia, Czechia, Hungary, Italy, Israel, Japan, Korea, Republic of, Germany, China, Ukraine, Romania, Argentina, Croatia, Brazil, Serbia, Russian Federation, Portugal, Bulgari... and more
Daiichi Sankyo, Inc.

Completed

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

Deep Vein Thrombosis | Venous Thromboembolism

Spain, United States, United Kingdom, India, France, Canada, Italy, Lebanon, Turkey
Daiichi Sankyo, Inc.

Completed

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Hepatic Impairment | Moderate Impaired Hepatic Function

United States
Daiichi Sankyo, Inc.

Completed

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

Pulmonary Embolism | Thrombotic Disease

Netherlands, Spain, United States, France, Austria, Belgium, Germany, Italy
Daiichi Sankyo, Inc.

Completed

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Pulmonary Embolism | Venous Thromboembolism (VTE) | Deep Vein Thrombosis (DVT)

United States, Israel, Spain, Czechia, Singapore, Canada, Argentina, Brazil, Bulgaria, Chile, Croatia, Denmark, El Salvador, France, Germany, Guatemala, Hungary, India, Kenya, Korea, Republic of, Lebanon, Malaysia, Netherlands, Norway, ... and more
Daiichi Sankyo, Inc.

Terminated

Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Daiichi Sankyo, Inc.

Completed

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Drug Interaction Potential

United States, New Zealand, Taiwan, Netherlands
Daiichi Sankyo, Inc.

Completed

Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV

United States
Daiichi Sankyo, Inc.

Terminated

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)

United States, France, United Kingdom
Daiichi Sankyo, Inc.

Completed

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

Hepatic Impairment

United States
Daiichi Sankyo, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
Daiichi Sankyo, Inc.

Completed

SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)

Cachexia

United States, Argentina, Chile, Guatemala, Honduras, Romania
Daiichi Sankyo, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)

Acute Spinal Cord Injury

France, Spain, United States, Canada, Czechia, Poland, United Kingdom
Daiichi Sankyo, Inc.

Terminated

Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy

Colorectal Cancer

United Kingdom, Russian Federation, Germany, Spain, Ukraine, Italy, France, Czechia, Poland
Daiichi Sankyo, Inc.

Terminated

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Anaplastic Thyroid Cancer

United States
Daiichi Sankyo, Inc.

Completed

An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia

Pain Associated With Fibromyalgia

Poland, Ukraine, Germany, Spain, United States, Austria, Portugal, Slovenia, Bulgaria, Romania, Serbia, Canada, Australia, Estonia, Russian Federation, New Zealand, Hungary, Denmark, Lithuania, Slovakia, South Africa, Latvia, Finland, Norwa... and more
Daiichi Sankyo, Inc.

Completed

Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers

Healthy Volunteers

United States
Daiichi Sankyo, Inc.

Completed

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Acute Myeloid Leukemia | Leukemia | AML | Myelodysplastic Syndrome | MDS

United States, Georgia
Daiichi Sankyo, Inc.

Completed

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

Colorectal Cancer | Neoplasms, Colorectal

United States, Peru, Chile, Argentina, Brazil
Daiichi Sankyo, Inc.

Completed

AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment (DESIRABLE)

Rheumatoid Arthritis

Japan
Daiichi Sankyo, Inc.

Completed

Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)

Atrial Fibrillation | Venous Thromboembolism

Clinical Trials Sponsored by Daiichi Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations